Printer Friendly

ALLIANCE PHARMACEUTICAL CORP. ANNOUNCES MARKETING APPROVAL FOR IMAGENT(R) GI

 SAN DIEGO, Aug. 16 /PRNewswire/ -- Alliance Pharmaceutical Corp. (NASDAQ: ALLP) announced today that its new drug application to market Imagent(R) GI has been approved by the U.S. Food and Drug Administration (FDA). Imagent GI is a liquid perfluorochemical known as perflubron, a new molecular entity. It is the first oral contrast agent for use with magnetic resonance (MR) imaging to be made available in the United States.
 Imagent GI contains no hydrogen, therefore it produces a dark image on all MR scanning modes. When present in the gastrointestinal tract, Imagent GI can enhance the delineation of the bowel in order to distinguish it from adjacent organs and areas of suspected pathology.
 The new drug application for Imagent GI was filed with the FDA in December 1990. In May 1992, the FDA Medical Imaging Drugs Advisory Committee unanimously recommended approval of the product.
 According to Duane J. Roth, chairman and chief executive officer of Alliance, "Imagent GI will address a potential U.S. market of approximately $35 to $50 million. However, the cost-control pressures currently surrounding MR imaging may affect our rate of market penetration in the near term," said Roth. "Nevertheless, this marketing approval is an important milestone for Alliance and further validates the medical utility of perfluorochemical-based drug products."
 Imagent GI will be manufactured at the company's Otisville, N.Y., facility and will be distributed by Picker Health Care Products. Picker is a distributor of radiology products, with over 65 representatives covering diagnostic imaging centers throughout the United States.
 Alliance is a leader in the development of proprietary pharmaceutical products based upon perfluorochemical and emulsion technologies. The company's efforts focus on two primary areas: diagnostic contrast agents for use with major imaging modalities to aid in the early diagnosis of certain cancers and other pathological conditions; and oxygen carriers for use as a temporary red blood cell substitute and as adjunctive treatments of various cardiovascular, cancer and respiratory conditions.
 -0- 8/16/93
 /CONTACT: Stuart Gauld of Alliance Pharmaceutical, 619-558-4300/
 (ALLP)


CO: Alliance Pharmaceutical Corp. ST: California IN: MTC SU: PDT

MF-JL -- SD002 -- 2844 08/16/93 07:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 16, 1993
Words:353
Previous Article:CHEMICAL LAUNCHES FAMILY OF BOND AND EQUITY FUNDS
Next Article:EDMARK REPORTS YEAR-END RESULTS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters